McGrath Yvonne 4
4 · iTeos Therapeutics, Inc. · Filed Mar 10, 2023
Insider Transaction Report
Form 4
McGrath Yvonne
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-03-09+130,000→ 130,000 totalExercise: $16.66Exp: 2033-03-09→ Common Stock (130,000 underlying)
Footnotes (1)
- [F1]This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.